Skip to main content

How effective is Mavenclad for MS?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Aug 2, 2024.

Official Answer by Drugs.com

In March 2019, the FDA approved Mavenclad (cladribine), a purine antimetabolite used for the treatment of relapsing forms of multiple sclerosis (MS) in adults 18 years of age and older. Mavenclad is used in relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). Mavenclad is not recommended for MS patients with clinically isolated syndrome or as a first-line agent due to its safety profile.

Mavenclad helps to reduce immune system cells (T and B cells) that can attack nerves and lead to inflammation in MS. The number of these cells will begin to recover after each yearly Mavenclad administration. This may take several months and your levels of immune system cells may not go back to pretreatment levels.

References

Read next

What are 8 key Mavenclad side effects to watch out for?

8 key side effects with Mavenclad use include a risk of cancer, birth defects in an unborn baby, a severe brain infection called PML, liver toxicity, other types of infections like shingles, tuberculosis or hepatitis, allergic reactions, heart failure and low white blood cell counts. Continue reading

How quickly does Mavenclad work?

Over 96 weeks, 81% of patients who took Mavenclad were relapse-free compared to 63% of those who took a placebo. Mavenclad also decreased 3-month progression of disability due to MS when compared to a placebo. Continue reading

Is Mavenclad a chemotherapy drug?

No, Mavenclad is not a chemotherapy (cancer) drug. It is an oral purine antimetabolite approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Mavenclad tablets are taken by mouth and are given as two yearly treatment courses. Continue reading

See also:

Related medical questions

Drug information

Related support groups